PressDecember 20, 2022 Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments
PressDecember 19, 2022 The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
PressDecember 19, 2022 Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders
PressDecember 19, 2022 Mydecine Innovations Group Announces Closing Under Share Subscription Agreement
PressDecember 15, 2022 PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
PressDecember 15, 2022 FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder
PressDecember 15, 2022 Filament Health and Psyence Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care
PressDecember 15, 2022 Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
PressDecember 14, 2022 Mindbloom Announces Rollout of Ketamine Telehealth Employee Benefits Program with Kennedy Care, 15Five
BlogDecember 14, 2022 Core One Labs : Subsidiary Vocan Biotechnologies Achieves Development Milestones
PressDecember 14, 2022 Numinus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022
PressDecember 14, 2022 Field Trip Health & Wellness To Webcast Live at the KCSA Mental Health Conference on December 15th
PressDecember 14, 2022 Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor
PressDecember 14, 2022 Small Pharma To Support University College London Research Project on Neuroplasticity
PressDecember 14, 2022 Tryp Therapeutics Announces Fiscal Year 2022 Financial Results and Reports Corporate Highlights
PressDecember 13, 2022 Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
PressDecember 13, 2022 Filament Health to Present Live at VirtualInvestorConferences.com December 15th
PressDecember 13, 2022 Awakn Life Sciences’ Phase III Trial to Be Delivered in the UK National Health Service
PressDecember 13, 2022 atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
